Rational approaches to targeted polypharmacology: creating and navigating protein-ligand interaction networks.
暂无分享,去创建一个
[1] Gavin Harper,et al. Assessment of chemical coverage of kinome space and its implications for kinase drug discovery. , 2008, Journal of medicinal chemistry.
[2] Avi Ma'ayan,et al. SNAVI: Desktop application for analysis and visualization of large-scale signaling networks , 2009, BMC Systems Biology.
[3] R. Solé,et al. The topology of drug-target interaction networks: implicit dependence on drug properties and target families. , 2009, Molecular bioSystems.
[4] F. Sams-Dodd,et al. Optimizing the discovery organization for innovation. , 2005, Drug discovery today.
[5] J. Devereux,et al. A comprehensive set of sequence analysis programs for the VAX , 1984, Nucleic Acids Res..
[6] B. Roth,et al. Magic shotguns versus magic bullets: selectively non-selective drugs for mood disorders and schizophrenia , 2004, Nature Reviews Drug Discovery.
[7] William P. Janzen,et al. A Chemogenomic Analysis of the Human Proteome: Application to Enzyme Families , 2007, Journal of biomolecular screening.
[8] F. Sams-Dodd. Target-based drug discovery: is something wrong? , 2005, Drug discovery today.
[9] R. Solé,et al. Data completeness—the Achilles heel of drug-target networks , 2008, Nature Biotechnology.
[10] A. Fliri,et al. Drug effects viewed from a signal transduction network perspective. , 2009, Journal of medicinal chemistry.
[11] M. Vieth,et al. Kinomics: characterizing the therapeutically validated kinase space. , 2005, Drug discovery today.
[12] G. V. Paolini,et al. Global mapping of pharmacological space , 2006, Nature Biotechnology.
[13] Gary D Bader,et al. How to visually interpret biological data using networks , 2009, Nature Biotechnology.
[14] Tudor I. Oprea,et al. Quantifying the Relationships among Drug Classes , 2008, J. Chem. Inf. Model..
[15] Ulrich A K Betz,et al. How many genomics targets can a portfolio afford? , 2005, Drug discovery today.
[16] M. Newman. The physics of networks , 2008 .
[17] Fidel Ramírez,et al. Computing topological parameters of biological networks , 2008, Bioinform..
[18] M. Vieth,et al. Kinomics-structural biology and chemogenomics of kinase inhibitors and targets. , 2004, Biochimica et biophysica acta.
[19] J. Mestres,et al. Drug‐Target Networks , 2010, Molecular informatics.
[20] Anne Mai Wassermann,et al. SARANEA: A Freely Available Program To Mine Structure-Activity and Structure-Selectivity Relationship Information in Compound Data Sets , 2010, J. Chem. Inf. Model..
[21] Pierre Acklin,et al. Similarity Metrics for Ligands Reflecting the Similarity of the Target Proteins , 2003, J. Chem. Inf. Comput. Sci..
[22] K. Ziegelbauer,et al. Genomics: success or failure to deliver drug targets? , 2005, Current opinion in chemical biology.
[23] K. Houck,et al. The Hypolipidemic Natural Product Guggulsterone Is a Promiscuous Steroid Receptor Ligand , 2005, Molecular Pharmacology.
[24] R. Morphy. Selectively nonselective kinase inhibition: striking the right balance. , 2010, Journal of medicinal chemistry.
[25] J. Pearl. Causal inference in statistics: An overview , 2009 .
[26] Michael J. Keiser,et al. Relating protein pharmacology by ligand chemistry , 2007, Nature Biotechnology.
[27] S. Frantz. Drug discovery: Playing dirty , 2005, Nature.
[28] Michael J. Keiser,et al. Predicting new molecular targets for known drugs , 2009, Nature.
[29] Tudor I. Oprea,et al. Systems Chemical Biology , 2019, Methods in Molecular Biology.
[30] Marie-Christine Brun,et al. TreeDyn: towards dynamic graphics and annotations for analyses of trees , 2006, BMC Bioinformatics.
[31] G. S. Johnson,et al. An Information-Intensive Approach to the Molecular Pharmacology of Cancer , 1997, Science.